For the quarter ended September 2024, Thermo Fisher Scientific (TMO) reported revenue of $10.6 billion, up 0.2% over the same period last year. EPS came in at $5.28, compared to $5.69 in the year-ago quarter.The reported revenue represents a surprise of -0.42% over the Zacks Consensus Estimate of $10.64 billion. With the consensus EPS estimate being $5.25, the EPS surprise was +0.57%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

Thermo Fisher Scientific Inc.'s (TMO) third-quarter 2024 adjusted earnings per share (EPS) of $5.28 beat the Zacks Consensus Estimate by 0.6%. However, the figure decreased 7.2% year over year.The adjusted number excludes certain expenses, including asset amortization costs and certain restructuring costs.GAAP EPS was $4.25, down 3.8% on a year-over-year basis.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, shares of TMO decreased nearly 2% in the ...

For Thermo Fisher Scientific Inc. (NYSE: TMO ), I highlighted the downturn in the pharma and biotech industry as well as weak growth in China in my previous article published in January 2024. I anticipate the overall pharmaAnalyst’s Disclosure: I/we have a beneficial long position in the shares of TMO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no b ...

Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Lab Consumables - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Lab Consumables is estimated at US$12.7 Million in 2023 and is projected to reach US$17.2 Million by 2030, growing at a CAGR of 4.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The manufacturing and supply of l ...

Core Viewpoint - Thermo Fisher Scientific (TMO) is expected to report a quarterly earnings per share (EPS) of $5.25, reflecting a 7.7% decline year-over-year, while revenues are forecasted to increase by 0.7% to $10.64 billion [1] Revenue Estimates - Analysts project 'Revenues- Laboratory Products and Biopharma Services' to be $5.67 billion, indicating a year-over-year decrease of 1% [2] - The estimated 'Revenues- Specialty Diagnostics' is $1.10 billion, reflecting a year-over-year increase of 1.3% [2] - 'Revenues- Life Sciences Solutions' is expected to reach $2.47 billion, showing a year-over-year increase of 1.7% [2] Geographic Revenue Estimates - 'Revenues- Analytical Instruments' is projected to be $1.85 billion, indicating a year-over-year increase of 5.5% [3] - 'Geographic Revenues- Customer Location- North America' is expected to be $5.64 billion, reflecting a decrease of 0.4% from the prior year [3] - 'Geographic Revenues- Customer Location- Asia-Pacific' is forecasted at $1.94 billion, indicating a year-over-year increase of 1.4% [3] - 'Geographic Revenues- Customer Location- Other regions' is estimated to reach $359.04 million, reflecting a year-over-year increase of 2.6% [3] - 'Geographic Revenues- Customer Location- Europe' is projected to be $2.70 billion, indicating a year-over-year increase of 2.2% [3] Stock Performance - Shares of Thermo Fisher have shown a return of -3.4% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3.8% [3]

The market expects Thermo Fisher Scientific (TMO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on October 23, 2024, might help the stock move higher if these ...

Core Viewpoint - Thermo Fisher Scientific Inc. is expected to report its third-quarter 2024 results on October 23, with mixed expectations for revenue and earnings performance compared to the previous year [1][2]. Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for Thermo Fisher's Q3 revenues is $10.64 billion, reflecting a 0.6% increase from the same quarter last year [2]. - The consensus estimate for earnings is $5.25 per share, indicating a 7.7% decline from the year-ago quarter [2]. - Earnings estimates have decreased by 0.6% in the past 30 days [3]. Group 2: Segment Performance Insights - The Analytical Instruments segment is anticipated to show strong sales growth, with projected revenues of $1.9 billion, representing a 12.7% year-over-year increase, driven by new product launches [5]. - The Life-Science Solutions segment is expected to generate $2.5 billion in revenues, marking a 2% improvement year over year, aided by the acquisition of Olink Holding AB [8]. - The Specialty Diagnostics segment is projected to report $1 billion in revenues, suggesting a 3.1% decline year over year, despite positive contributions from transplant diagnostics and immunodiagnostics [11]. Group 3: Recent Developments and Innovations - The company launched several new products, including the Thermo Scientific Stellar Mass Spectrometer and new editions of the ThermoScientific Orbitrap Ascend Tribrid Mass Spectrometer, which are expected to enhance revenue [4][5]. - A new bio-based film for single-use technologies was introduced, contributing to growth in the bioproduction business [7]. - Recent partnerships and product launches, such as the CorEvitas Adolescent Atopic Dermatitis Registry and the myeloMATCH trial with the National Cancer Institute, are expected to positively impact the company's performance [9][10]. Group 4: Operational Expansion - Thermo Fisher opened a new electron microscopy demo center in Taiwan and expanded its global laboratory services with a new bioanalytical lab in Sweden, which may favorably influence revenue [12][13].

Thermo Fisher Scientific Inc. (TMO) is making robust progress with its growth strategy, which bodes well for the upcoming quarters. The spree of innovative product introductions bolsters its portfolio. The company's Bioproduction business is expanding and increasing its capacity to meet the rising demand. Meanwhile, the adverse macroeconomic impacts and currency fluctuations raise concerns for TMO's operations, In the past year, shares of this Zacks Rank #3 (Hold) company have rallied 20.7% compared with th ...

Thermo Fisher Scientific Inc. (NYSE: TMO ) has been one of the best-performing stocks over the last decade, with shares returning more than 420% over this period. I've written about investing for Seeking Alpha since 2015 and for Sure Dividend since 2018. I focus primarily on owning shares of companies that have demonstrated long histories of dividend growth. These types of companies have largely proven successful at raising dividends through multiple recessionary periods, a sign that their business models a ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Thermo Fisher Scientific (TMO) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider. When looking at the last two reports, this maker of scientific instrument and laboratory supplies has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 6.70%, on average, in the ...